The semaglutide patent for Ozempic and Wegovy expired in India on March 20. Novo Nordisk India MD Vikrant Shrotriya said generics could enter and reshape the market, implying increased competition and likely downward pressure on prices and market share for Novo Nordisk products in India. This presents a potential headwind to Novo Nordisk's India sales and margins if generic uptake is rapid; impact is likely localized to the Indian market in the near term.
The semaglutide patent for Ozempic and Wegovy expired in India on March 20. Novo Nordisk India MD Vikrant Shrotriya said generics could enter and reshape the market, implying increased competition and likely downward pressure on prices and market share for Novo Nordisk products in India. This presents a potential headwind to Novo Nordisk's India sales and margins if generic uptake is rapid; impact is likely localized to the Indian market in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
